An Jella

Short-Term Outcomes of Hydrus Microstent With and Without Additional Canaloplasty During Cataract Surgery.

Microstent combined with canaloplasty resulted in a significantly higher rate of medication-free status compared with microstent alone through 6 months.

MicroPulse Transscleral Laser Therapy Dosimetry Utilizing the Revised P3 Delivery Device: A Randomized Controlled Trial.

This study demonstrates a dose-response relationship with improved IOP control and excellent safety profile in patients treated with higher treatment total energy and fluence using the revised MPTLT probe.

Clinical Outcomes of Hydrus Microstent Implantation for Open-Angle Glaucoma: Results from a Large Academic Center.

In this nontrial setting, cataract surgery with Hydrus Microstent implantation was associated with sustained reductions in IOP, glaucoma medication burden, and disease progression rate.

Treatment Outcomes of Micropulse Transscleral Laser Therapy as an Adjunctive Therapy in African American Individuals With Prior Procedural Interventions.

Micropulse is an effective adjunctive treatment in African Americans with severe-stage primary open angle glaucoma and a history of prior glaucoma procedures.